The US holds the highest share at nearly 50% in the EP ablation market. Credit: MAD.vertise via Shutterstock.

The landscape of electrophysiology (EP) ablation catheters has seen significant advancements in recent years, especially with the introduction of pulsed-field ablation (PFA).

In December 2023, Medtronic received US Food and Drug Administration (FDA) approval for its PFA system, PulseSelect, making this the first PFA catheter to be commercially available in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Medtronic is not the first company to enter the PFA space, since Boston Scientific already has shares in Europe after receiving Conformité Européenne approval for its Farapulse system in 2021.

However, the US currently has the highest share at almost 50% in the EP ablation market. In comparison, Europe only has a market share of approximately 39% in this $2.8bn market.

The lucrativeness of the US PFA market has attracted large medtech players such as Medtronic, Boston Scientific, and Johnson & Johnson. However, Medtronic is the first company to gain FDA approval for its PFA catheter system.

See Also:

Despite Medtronic winning this race after securing approval in December 2023, Boston Scientific secured FDA approval for its Farapulse system in the US earlier this week.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

If Boston Scientific’s intended timeline succeeds, it will then be the only company to have shares in the PFA market in two major regions (the US and Europe), ending Medtronic’s brief PFA monopoly period.

Unlike its two other counterparts, Johnson & Johnson has not had much success in its clinical trials that could lead to FDA approval with its PFA system, the Varipulse.

Instead, the company managed to receive approval for the Varipulse system in Japan.

This means that all three companies currently dominate a specific geographic region in the PFA space: Medtronic in North America, Boston Scientific in Europe, and Johnson & Johnson in Asia.